BioTuesdays

Roth starts Actinium Pharma at buy

Roth Capital Partners initiated coverage of Actinium Pharmaceuticals (NYSE MKT:ATNM) with a “buy” rating and $5 price target. The stock closed at $1.66 on Wednesday.

“We believe it is an opportune time to explore the investment case of Actinium based on the late-stage nature of the lead asset, addressing unmet medical needs, clinical data in hand, and a broad set of upcoming catalysts,” writes analyst Joseph Pantginis.

Actinium is developing radio immunotherapy products for the treatment of cancer. The two lead assets, Iomab-B and Actimab-A, are being developed for bone marrow transplant (BMT) conditioning and AML, respectively.

The company also is considering a potential application for breakthrough therapy designation for one or both of products.

Iomab-B is in an ongoing Phase 3 SIERRA study in BMT conditioning with relapsed/refractory AML patients, which should read out in the second half of 2018, Mr. Pantginis said. Actimab-A is in an ongoing Phase 1/2 in front-line AML.

The company was also recently granted SME (small and medium-sized enterprises) status in the EU, which is somewhat analogous to breakthrough therapy designation in the U.S. and allows for enhanced regulatory support.

Subscribe

Sign up to our weekly BioTuesdays newsletter.

Subscribe

Sign up to our weekly BioTuesdays newsletter.